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Abstract Variability and modiﬁcation of the symptoms
of Huntington’s disease (HD) are commonly observed in
both patient populations and animal models of the disease.
Utilizing a stable line of the R6/2 HD mouse model, the
present study investigated the role of genetic background in
the onset and severity of HD symptoms in a transgenic
mouse. R6/2 congenic C57BL/6J and C57BL/6J 9 DBA/
2J F1 (B6D2F1) mice were evaluated for survival and a
number of behavioral phenotypes. This study reports that
the presence of the DBA/2J allele results in amelioration or
exacerbation of several HD-like phenotypes characteristic
of the R6/2 mouse model and indicates the presence of
dominant genetic modiﬁers of HD symptoms. This study is
the ﬁrst step in identifying genes that confer natural genetic
variation and modify the HD symptoms. This identiﬁcation
may lead to novel targets for treatment and help elucidate
the molecular mechanisms of HD pathogenesis.
Introduction
Huntington’s disease (HD) is a progressive neurodegener-
ative disorder caused by an expansion of the polyglutamine
(Q) tract in the human Huntington’s disease gene HTT.H D
exhibits complete penetrance with 40Q or more but can
occur in individuals with as few as 35Q. The hallmark
symptoms of HD include a variety of motor, cognitive, and
psychiatric symptoms, but speciﬁc phenotypes present with
a large degree of heterogeneity. While repeat length is the
strongest predictor for age of onset and accounts for *70%
of the age-of-onset variation in HD (Andrew et al. 1993;
Brinkman et al. 1997; Duyao et al. 1993; Snell et al. 1993;
Stine et al. 1993), little is known about the factors that
contribute to the remaining 30% of variability observed. In
patients, the strongest correlation for the remaining age-of-
onset variation and heterogeneity in psychiatric symptoms
is family history (Djousse et al. 2003; Lovestone et al.
1996; Rosenblatt et al. 2001; Squitieri et al. 2000; Telenius
et al. 1993; Tsuang et al. 1998, 2000; Wexler et al. 2004),
suggesting the inﬂuence of genetic and environmental
factors beyond the disease gene in the variability of HD
onset, symptoms, and progression. Evidence for genetic
modiﬁcation of HD has been found in several patient
population studies (Djousse et al. 2004; Gayan et al. 2008;
Li et al. 2003, 2006; Metzger et al. 2006a, b, 2008;
Taherzadeh-Fard et al. 2009) as well as animal models,
including yeast (Giorgini et al. 2005), Drosophila (Branco
et al. 2008), and mice (Van Raamsdonk et al. 2007).
Although many symptoms of HD can be easily studied
in mice (e.g., activity, motor coordination, sensorimotor
gating, and anxiety) and are modulated by genetic back-
ground (Bolivar et al. 2000; Crawley et al. 1997; Rogers
et al. 1999; Spencer et al. 2011; Van Raamsdonk et al.
2007), to date no studies to identify modiﬁers of HD have
been performed using an unbiased screen in a mouse
model. The early onset and severity of disease phenotypes
make the R6/2 HD mouse model ideal for an unbiased
modiﬁer screen (Mangiarini et al. 1996). In a recent study
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R6/2 line exhibiting a relatively stable polyglutamine
expansion (Cowin et al. 2011). Utilizing the advantages
provided by this R6/2 line (i.e., pure genetic background,
early disease onset, and intergenerational repeat stability),
we bred the C57BL/6J (B6) 110Q R6/2 mice to inbred
DBA/2J (D2) mice to generate an F1 cross of B6D2F1 (F1)
mice. Utilizing this breeding strategy, we assessed whether
behavioral responses of B6 R6/2 mice can be altered by the
presence of a D2 allele. The ﬁndings from the present study
indicate that HD-related phenotypes can indeed be modi-
ﬁed by a change in genetic background in R6/2 mice and
suggest the existence of dominant genetic modiﬁers that
both ameliorate and exacerbate HD-like symptoms.
Materials and methods
Animals
C57BL/6J (B6) female mice carrying ovaries from con-
genic B6 110-polyglutamine (110Q) R6/2 females were
obtained from the Jackson Laboratory (Bar Harbor, ME)
(Cowin et al. 2011). The ovarian-transferred female mice
were bred to male B6 or male DBA2/J (D2) mice creating
two lines of R6/2 and wild-type mice: B6 and B6D2F1.
Mice were housed two to ﬁve per cage with a 12-h light
cycle. Food and water were provided ad libitum. Animal
care and testing was approved by the Baylor College of
Medicine Animal Care and Use Committee and in accor-
dance with NIH guidelines.
Genotyping and CAG repeat length
Mice were genotyped using PCR ampliﬁcation of tail DNA.
Primers (50-GCCGCTCAGGTTCTGCTTT-30 and 50-AA
GGCCTTCATCAGCTTTTCC-30)were usedtoamplifythe
50 region of the transgene, yielding a 150-bp product in
transgenic samples. Polyglutamine expansion size was
monitored in all mice using tissue obtained from ear clips.
Laragen, Inc. (Los Angeles, CA, USA) measured polyglu-
tamine length from ear clip DNA using Genescan and
sequencing modes on an ABI 377 sequencer. Mice used in
this study had repeats ranging from 107 to 120 CAG.
Morbidity analysis
Mice were monitored daily before noon for symptoms of
morbidity. Morbidity was determined when all of the fol-
lowing phenotypes were present: kyphosis, tremor, body
weight loss, and immobility. When all these phenotypes
were present, the animal was near death (i.e., within
1–3 days), and on some occasions mice were found dead.
When morbidity was determined, mice were euthanized.
Age at morbidity was recorded and analyzed as percent
‘‘survival’’ using Kaplan–Meier analysis and v
2 test for
signiﬁcance. The numbers for each age group tested were as
follows:B6,n = 48Tgfemales,n = 60Tgmales;B6D2F1,
n = 35 Tg females, n = 45 Tg males. The repeat range for
miceusedinthisexperimentwas108–113inB6Tgmiceand
107–112 in B6D2F1 Tg mice (Tg = transgenic).
Behavioral testing
Male and female 110Q mice underwent a battery of
behavioral tests performed in the following order: (1) open-
ﬁeld activity, (2) rotarod, (3) prepulse inhibition (PPI), and
(4) passive avoidance assay (PA). Mice underwent no more
than one test per day and each test was performed with
1–3 days in between. Testing was completed over a 10-day
period. Before testing each day, mice were given a 30-min
rest period after being moved to the testing room. All
experiments were carried out between 8 a.m. and 1 p.m.
The numbers for each age group tested were as follows:
8-week-old B6, n = 4 Tg females, n = 6 Tg males, n = 3
Wt females, n = 7 Wt males; 8-week-old B6D2F1, n = 12
Tg females, n = 10 Tg males, n = 17 Wt females, n = 13
Wt males (Wt = wild-type). Naive mice were used in each
group. The average repeat length for mice used in behav-
ioral experiments was 110.10 ± 0.433 SEM for B6 R6/2
mice and 110.36 ± 0.429 SEM for B6D2F1 R6/2 mice.
Open-ﬁeld activity
Mice were placed in the center of a clear Plexiglas arena
(40 cm 9 40 cm 9 30 cm). Testing was 30 min long,
during which time mice explored freely. During testing,
800 lx overhead lighting was positioned above the cham-
ber and 55-dB white noise was presented. During testing,
the VersaMax Animal Activity Monitoring System
(AccuScan Instruments, Inc., Columbus, OH, USA) was
used to monitor and record activity as detected by photo-
beam interruptions. Beam breaks were recorded over 2-min
intervals throughout the test period. Data from the entire
30-min test were analyzed in measures of total distance
traveled, vertical beam breaks, and distance traveled in the
center of the arena (22.5 cm 9 22.5 cm). The center dis-
tance was divided by the total distance (center:total dis-
tance ratio) and used as an index for anxiety-like behaviors
(Mathis et al. 1994; Treit and Fundytus 1988).
Rotarod
Prior to rotarod testing, the body weight for each mouse
was recorded. To measure motor skill and learning, mice
were placed on an UGO Basile Accelerating Rota-Rod
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latency to fall or lose balance was recorded. If a mouse lost
its balance and was not walking on top of the beam but
continued to hold on to the rod, the time to the ﬁrst full
revolution was used. The rotation of the rod accelerated
from 4 to 40 rpm over a 5-min trial. Mice were given four
trials per day over two consecutive days. There was a
minimum of 20 min between each trial. Latency to fall (or
lose balance but ride around one full revolution) was
averaged across all eight trials and analyzed.
Prepulse inhibition
Acoustic startle responses to indicate sensorimotor gating
performance were measured using the SR-Lab System (San
Diego Instruments, San Diego, CA, USA). Mice were
placed inside holding tubes and an initial 5-min 70-dB
background noise was presented. A test session included
six blocks of trials presented in a pseudorandom order.
Each block included eight trial types with each trial type
presented once; intertrial intervals were 10–20 s. The
‘‘startle-only’’ trial type was a 40-ms 120-dB sound. Pre-
pulses of 4, 8, and 12 dB above the 70-dB background
were used. Another three trial types included both prepulse
and acoustic startle stimuli. In these trial types, prepulses
were 20 ms in duration and were presented 100 ms before
the startle stimulus. The last trial type consisted of back-
ground noise and was used for measuring baseline move-
ment inside the holding tube. Responses were measured for
65 ms following stimulus presentation. Maximum startle
amplitude was used as the dependent variable and mice
with startle amplitude less than 100 were excluded from
study results.
Percent PPI of a startle response for each prepulse level
was calculated as follows:
100  ½

startle response on acoustic prepulse
þ startle stimulus trials=startle response alone trials)
  100 :
The average PPI of all three prepulse intensities was used
as the measure for this experiment.
Passive avoidance (PA)
This test was conducted in a two-chamber box
(42 cm 9 16 cm 9 21 cm) (Med Associates, St. Albans,
VT, USA) divided by a white partition containing a sliding
door. One chamber was clear and brightly lit (approxi-
mately 800 lx) while the other was covered and kept dark.
Each day of this 3-day test mice were transferred from a
cage to the bright chamber and the partition was opened
after 10 s. Each day the latency to enter the dark side was
recorded, with a maximum of 300 s. On days 1 and 2, after
a mouse entered the dark, the partition door was closed and
a 2-s 0.75-mA foot shock was administered via a grid ﬂoor;
after 10 s the mouse was returned to its home cage.
Approximately 24 h passed between testing days. Vocali-
zation was noted as an indication that the animal detected
the foot shock stimulus.
Statistical analyses for behavior
Comparisons were made between genotypes independently
at each age. Data for OFA, body weight, acoustic startle
response, and PA were analyzed using three-way (genetic
background 9 genotype 9 gender) analysis of variance
(ANOVA). RROD and PPI were analyzed using three-way
ANOVA with repeated measures. When interactions were
identiﬁed, further statistical analyses were performed using
simple-effects tests. Analyses revealed changes in pheno-
typic expression across gender in some assays. For sim-
plicity, all ﬁgures represent data from both genders.
Transgene expression analysis
Mice used in time-resolved (TR-FRET) experiments
expressed a mutant transgene with an average of 110 CAG
for both lines (B6, 110.83 ± 0.401 SEM; B6D2F1,
109.50 ± 0.992 SEM).
Tissue collection
Upon completion of behavior studies, mice were killed by
cervical dislocation and whole-brain tissue was immedi-
ately removed and stored in Ambion RNAlater tissue
collection RNA stabilization solution (Applied Biosystems/
Ambion, Austin, TX) at 4C for 1–7 days, after which
tissue was removed from excess RNAlater solution and
stored at -80C.
Protein isolation and TR-FRET analysis
Crude brain tissue homogenates from 8-week-old B6 Tg
(n = 6), 8-week-old B6 Wt (n = 4), 8-week-old B6D2F1
Tg (n = 6), and 8-week-old B6D2F1 Wt (n = 4) were
prepared as described previously in collaboration with
Novartis Pharmaceuticals, Inc. (Cowin et al. 2011). Brieﬂy,
tissue was homogenized in 109 w/v lysis buffer
[PBS ? 1% Triton X-100 ? Complete Protease Inhibitor
(Roche, Switzerland)]. Five microliters of homogenate and
1 ll detection buffer (50 mM NaH2PO4, 400 mM NaF,
0.1% BSA, and 0.05% Tween ? antibody mix) were
mixed to a ﬁnal antibody concentration of 1 ng 2B7-Tb ?
10 ng MW1-d2 and 1 ng 4C9-Tb ? 10 ng 4C9-Alexa488
(in each sample) for the quantiﬁcation of soluble mutant
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Samples were analyzed with an EnVision Reader (Perk-
inElmer, Waltham, MA). The donor ﬂuorophore terbium
was excited at 320 nm. After a 100-ls delay, terbium, d2,
and Alexa488 emission signals were read out for 200 lsa t
620, 665, and 520 nm, respectively. Data are presented as
the fold change in signal over background. TR-FRET data
were analyzed using one-way ANOVA for a main effect of
genetic background. Independent comparisons were made
for soluble and aggregated protein measures.
Results
To determine whether the presence of a D2 allele produced
modiﬁcation of disease phenotypes of HD or progression in
the B6D2F1 relative to congenic B6 110Q R6/2 mice,
behavioral analysis was performed. Mice of both genetic
backgrounds were tested at 8 weeks of age in a variety of
experiments to assay amelioration or exacerbation in phe-
notypes previously identiﬁed in pure B6 R6/2 mice,
including motor coordination, exploratory activity, anxi-
ety-related responses, sensorimotor gating, learning, and
memory as well as soluble and aggregated mHTT protein
levels (Cowin et al. 2011).
B6D2F1 transgenic mice exhibit delayed onset
of morbidity relative to R6/2 mice in the B6 genetic
background
Mice were monitored daily for signs of end-stage disease
phenotypes, including resting tremors, loss of grooming,
inactivity, and others (see ‘‘Materials and methods’’ sec-
tion). Animals that were determined to meet the require-
ments for morbidity were euthanized immediately in
accordance with the guideline set forth by the Baylor
College of Medicine Animal Care and Use Committee. The
age at which each animal was euthanized was recorded,
and differences in percent survival (i.e., morbidity or death)
in the two genetic backgrounds were analyzed. We
observed a signiﬁcant delay (v
2 = 69.309, P\0.001;
Fig. 1) in the onset of morbidity in the R6/2 F1 mice
(107.06 ± 1.38 days) compared to the congenic B6 mice
(78.94 ± 2.01 days).
Presence of the D2 allele modulates activity in wild-
type and R6/2 mice, relative to activity levels observed
in the B6 background
Mice were tested in the open-ﬁeld assay to assess changes
in activity and exploration. Genotype effects were depen-
dent on genetic background and gender as revealed by the
signiﬁcant genetic background 9 genotype 9 gender
interaction [F(1.64) = 4.417, P\0.040]. Follow-up anal-
ysis of the interaction revealed that the genotype effect was
present in both genders in the B6 background but only in
female B6D2F1 mice. Speciﬁcally, B6 transgenic mice
explored less than B6 wild-type animals at 8 weeks of age
(P\0.001) (Fig. 2a). Also, while male F1 transgenics
explored in similar fashion to male F1 wild-type littermates
(P = 0.882), exploration in female F1 R6/2 mice was
increased relative to controls (P = 0.023). In addition,
simple-effects analyses revealed that transgenic F1 mice of
both genders explored signiﬁcantly more than B6 transgen-
ics (P B 0.037). Wild-type mice from the F1 line exhibited
decreased levels of exploration relative to B6 control mice
(P B 0.031). A main effect of genotype was also observed
[F(1.64) = 18.195, P\0.001].
A signiﬁcant genetic background 9 genotype interac-
tion [F(1.64) = 14.848, P\0.001] was found in open-
ﬁeld rearing activity. Simple-effects analysis revealed that
transgenic mice of both genetic backgrounds rear signiﬁ-
cantly less than littermate controls (P\0.002). In contrast
to performance measures of total distance traveled in the
open ﬁeld, the number of vertical beam breaks or bouts of
rearing was similar (P = 0.180) in wild-type mice from
both genetic backgrounds. A clear improvement, however,
was observed among transgenics in the B6D2F1 back-
ground relative to B6 mutant mice (P\0.001) (Fig. 2b).
Rearing behavior in the open ﬁeld also revealed main
effects of genotype [F(1.64) = 51.695, P\0.001] and
gender [F(1.64) = 7.309, P = 0.009], with transgenics and
female mice exhibiting signiﬁcantly lower rearing (irre-
spective of genetic background) than wild-type and male
mice, respectively.
Anxiety-like behaviors in the open ﬁeld are modulated
by genetic background
Anxiety-like behavior in the open ﬁeld is measured by
dividing the distance traveled in the center of ﬁeld by the
total distance traveled in the entire ﬁeld giving a value for
Fig. 1 Kaplan–Meier curve of the percent survival of B6 and
B6D2F1 transgenic mice over several weeks. B6D2F1 transgenic
mice show a signiﬁcant delay in the onset of morbidity, P\0.001
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shown to be sensitive to the effects of anxiolytic drugs
(Mathis et al. 1994; Treit and Fundytus 1988) suggesting
that a lower ratio is indicative of increased anxiety or
anxiety-like behaviors. Unlike other measures of the open
ﬁeld assay, no signiﬁcant interactions were found (P C
0.069).However,analysisofcenter:totaldistanceratiosinthe
open ﬁeld did uncover main effects of genetic background
[F(1.64) = 60.603, P\0.001], genotype [F(1.64) = 5.960,
P = 0.017], and gender [F(1.64) = 4.316, P = 0.042]
(Fig. 2c). Overall, B6D2F1 mice had signiﬁcantly lower
center:total distance ratios than B6 mice. In addition, trans-
genic mice exhibited lower center:total distance ratios than
wild-types and females showed more anxiety-like behavior
than male mice.
Motor impairments on the rotarod assay are
exacerbated in B6D2F1 110Q mice
Differences in performance on the rotarod motor coordina-
tion task were observed in 110Q R6/2 mice of differ-
ent genetic backgrounds and genotypes. Day 9 genotype
[F(1.64) = 17.803, P\0.001] and day 9 genetic back-
ground [F(1.64) = 4.746, P = 0.033] interactions were
found. Simple-effects analysis of the signiﬁcant day 9
genotype interaction showed that in both B6 and B6D2F1
genetic backgrounds, the latency to fall of transgenic mice
wassigniﬁcantlybelowthatofwild-typeperformancelevels
on rotarod testing days 1 and 2 (P\0.001). However, there
wasoverallimprovementinperformanceforbothtransgenic
and wild-type mice and mice in both B6 and B6D2F1
backgrounds on day 2 compared to performance on
day 1 (P\0.001) (Fig. 3). In addition, the data revealed a
worsening of the motor impairment phenotypes in the
B6D2F1backgroundrelativetoB6miceonbothtestingdays
(P B 0.002).Athirdinteraction,genotype 9 line[F(1.64) =
4.906, P = 0.030], was also observed. Follow-up analyses
Fig. 2 Activity and exploration in the open-ﬁeld assay is modiﬁed in
B6D2F1 transgenic mice. a Exploratory activity as measured by total
distance traveled in an open ﬁeld. b Rearing behavior as measured by
vertical activity (beam interruptions). In both (a) and (b), ‘‘a’’
represents transgenic mice that are signiﬁcantly less active than wild-
type littermates and ‘‘b’’ represents B6 transgenic mice that are less
active than B6D2F1 transgenics. c Anxiety-like responses as
measured by the center:total distance ratio. *Represents transgenic
mice that spend less of their exploration in the center of the open ﬁeld
relative to wild-type mice overall. **Represents B6 mice that spend
more time in the center of the open ﬁeld than B6D2F1 mice overall.
All P values B0.042 by three-way ANOVA and simple-effects
analysis
Fig. 3 Impaired motor coordination and skill learning on the rotarod
is exacerbated in B6D2F1 transgenic mice. Latency to fall from the
rotarod was recorded and, in all cases, transgenic mice were impaired
relative to wild-type littermates in both genetic backgrounds and on
both days of testing (P\0.001). In addition, all genotypes and lines
showed signiﬁcant improvement in rotarod performance between
days 1 and 2 (P\0.001). Overall, B6D2F1 mice were impaired
relative to B6 mice through the experiment irrespective of genotype
(P B 0.002)
R.-M. Cowin et al.: Genetic background modulates behavioral impairments in R6/2 mice 371
123showedthatinbothlines,transgenicmiceexhibitsigniﬁcantly
less motor skill than control littermates (P\0.001), but it
revealed that the increase in rotarod impairments of F1 mice
relative to B6 was limited to the transgenic genotype
(P\0.001). Wild-type mice performed in a similar fashion
on both genetic backgrounds (P = 0.062). In addition, the
main effects of testing day [F(1.64) = 88.455, P\0.001],
genetic background [F(1.64) = 24.140, P\0.001], and
genotype [F(1.64) = 80.236, P\0.001] were identiﬁed.
Speciﬁcally, overall performance on day 2 was signiﬁcantly
better than that on day 1, B6D2F1 mice exhibited poorer
performance than B6 mice, and transgenic mice were
impaired relative to wild-type controls.
Reduced-weight phenotypes are rescued in B6D2F1
110Q R6/2 mice
Both genetic background and genotype strongly inﬂuenced
body weight in 110Q R6/2 mice. A signiﬁcant genetic
background 9 genotype interaction [F(1.64) = 23.756,
P\0.001] was identiﬁed and follow-up analyses revealed
background-dependent weight phenotypes in transgenics.
Speciﬁcally, reduced-weight phenotypes were present only
in congenic B6 R6/2 mice (P\0.001, Fig. 4). B6D2F1
transgenic mice showed a full rescue of this phenotype,
with weight similar to that of control littermates
(P = 0.787) and signiﬁcantly more than that of B6 trans-
genic mice (P\0.001, Fig. 4). These data also revealed
main effects of genetic background [F(1.109) = 45.979,
P\0.001], genotype [F(1.109) = 26.544, P\0.001],
and gender [F(1.64) = 143.824, P\0.001]. Overall body
weight of B6D2F1 mice, irrespective of genotype, was
higher than that of B6 mice and, not unexpectedly, female
mice, irrespective of genetic background or genotype,
weighed less than male mice.
Genetic background modulates acoustic startle
responses and PPI but does not alter the phenotypic
effects of HD on startle inhibition in R6/2 mice
Acoustic startle responses revealed a triple interaction of
genetic background 9 genotype 9 gender [F(1.64) = 4.917,
P = 0.030]. Simple-effects analysis revealed a genotype
difference only in male B6 mice. Speciﬁcally, B6 R6/2
males exhibited a signiﬁcantly lower startle response than
B6 male wild-type mice (P\0.001). In addition, differ-
ences in startle response between the B6 and F1 back-
grounds were found for both wild-type and transgenic
mice, irrespective of genotype. In all comparisons, F1 mice
exhibited a signiﬁcantly lower startle response than geno-
type- and gender-matched B6 mice (P\0.001; Fig. 5a).
Gender differences were observed, but only in wild-type
B6 mice (P\0.001). Main effects of genotype [F(1.64) =
13.341, P = 0.001], genetic background [F(1.64) = 178.035,
Fig. 4 Reduced body weight in transgenic mice is rescued in the
B6D2F1 background. ‘‘a’’ represents that R6/2 were signiﬁcantly
different from wild types and ‘‘b’’ denotes an increase in body weight
between B6 and B6D2F1 transgenic mice. All P values \0.001 by
three-way ANOVA and simple-effects analysis
Fig. 5 Sensorimotor gating. a Acoustic startle response measure-
ments. Both transgenic and wild-type B6D2F1 mice show reduced
startle phenotypes relative to B6 mice. b Percent PPI of wild-type and
transgenic mice at each prepulse. Average PPI was normal in mice in
both genetic backgrounds at 8 weeks of age but decreased inhibition
was observed by 10 weeks. Overall, B6D2F1 mice show increased
inhibition compared to B6 mice. In (a) **Reﬂects a difference in
performance between different genetic backgrounds (P\0.001)
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also identiﬁed. Overall, transgenic, B6D2F1 and female mice
exhibited a lower startle amplitude than wild-type, B6, and
male mice, respectively.
PPI revealed an overall effect of the prepulse
[F(2.64) = 6.392, P = 0.002] but no interactions with
genotype, line, or gender were identiﬁed (Fig. 5b). How-
ever, a main effect of genetic background was observed
[F(1.64) = 4.426, P = 0.039]. Despite a reduced startle
response in the F1 genetic background, B6D2F1 mice
exhibited an overall signiﬁcant increase in percent inhibi-
tion relative to B6 mice (Fig. 5b).
PA performance is affected by genetic background
and late-age impairments in transgenic mice are
rescued by the D2 allele
We previously identiﬁed a reduction in PA inhibition in B6
110Q R6/2 mice (Cowin et al. 2011). To investigate
whether this phenotype is sensitive to the genetic back-
ground, we tested both B6 and F1 lines of R6/2 mice in this
striatal-based task (Lorenzini et al. 1995; Prado-Alcala
et al. 1985). Performance of naı ¨ve mice on training day 1
revealed no signiﬁcant differences in genetic background,
genotype, or gender and no interactions were found
(P C 0.076; Fig. 6a).
Analysis of day 2 latencies revealed a genetic back-
ground 9 genotype interaction [F(1.63) = 10.971, P =
0.002]. Simple-effects analysis showed that while mice in
the B6 background had no signiﬁcant difference between
wild-typeandtransgenicperformanceinday2performances
for this study (P = 0.861), B6D2F1 mice exhibited geno-
type differences (P\0.001). Speciﬁcally, F1 transgenic
mice exhibited a shorter latency to enter the dark chamber
(Fig. 6b). In addition, data from day 2 show that although
transgenicmicefrombothgeneticbackgroundsperformedin
a similar fashion at both ages tested (P = 0.413), wild-type
mice in the F1 background took signiﬁcantly longer than B6
wild-type mice to enter the dark (P\0.001). In addition,
data from day 2 revealed main effects of both genetic
background [F(1.63) = 20.031, P\0.001] and genotype
[F(1.63) = 9.066, P = 0.004].
In the PA assay, day 2 serves not only as a test for the
learned association of the dark chamber and a foot shock
pairing following day 1 of training, but also as a second
training day. After entering the dark chamber on day 2, the
mice receive a second presentation of the dark chamber—
foot shock pairing. Follow-up testing on day 3 is performed
to assess learning after two training sessions (foot shocks
received on days 1 and 2). In this study, performance on
day 3 showed a genetic background 9 gender interaction
[F(1.63) = 8.841, P = 0.004]. Simple-effects analysis
identiﬁed differences between genetic backgrounds in
female mice. B6D2F1 female mice showed signiﬁcantly
longer latencies than B6 females (P\0.001; Fig. 6c).
In addition, an overall effect of genetic background
[F(1.63) = 12.911, P = 0.001] but not genotype was
identiﬁed, indicating normal learning in the PA assay by
day 3 for both B6 and F1 mice in the present study.
Fig. 6 PA learning. a Latency to enter the dark on training day 1.
b Latency to enter the dark on test day 2. c Latency to enter the dark
on test day 3. No differences in performance between transgenic and
wild-type mice were found in either genetic background on day 1. In
addition, no signiﬁcant difference between genetic backgrounds,
irrespective of genotype, was identiﬁed for day 1 latencies. B6D2F1
transgenic mice exhibited lower latencies to enter the dark than
B6D2F1 wild-type mice on day 2, but by day 3 they showed improved
learning. In (b), ‘‘a’’ represents a decreased latency to enter the dark
in transgenic mice compared to wild types. In (c) **Represents the
overall increase in latency in B6D2F1 transgenics compared to B6
transgenic mice. All P values B0.001 by three-way ANOVA and
simple-effects analysis
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of soluble mutant protein but not aggregated protein
In addition to investigating a role for genetic background in
behavioral phenotype modulation, we analyzed mHTT
protein levels in each line of R6/2 mice as a molecular
marker of disease using TR-FRET to assess both soluble
and aggregated mHTT protein (Weiss et al. 2009). B6 and
B6D2F1 mice showed a signiﬁcant difference in the level
of soluble mHTT [F(1.8) = 9.215, P = 0.016]. Speciﬁ-
cally, B6D2F1 mice maintained higher levels of soluble
mHTT than B6 transgenics (Fig. 7). This increase was
speciﬁc to soluble mHTT, however, and genetic back-
ground had no effect on the level of aggregated mHTT
present [F(1.8) = 0.947, P = 0.359] (Fig. 7).
Discussion
Genetic background is known to inﬂuence many aspects of
behavior in both wild-type and mutant mice (Menalled
et al. 2009; Van Raamsdonk et al. 2007). This report pre-
sents the effects of genetic background in an F1 study of
R6/2 mice carrying 110Q. Mice in both congenic B6 and
hybrid B6D2F1 backgrounds were tested in a variety of
behavioral tasks known to be impaired in congenic B6 R6/
2 mice at 8 weeks old (Cowin et al. 2011). In many of these
tasks, the effect of the transgene was dependent on the
genetic background, providing evidence for the inﬂuence
of dominant modiﬁers of the B6 R6/2 phenotype by the
presence of a D2 allele. However, it is important to note
that in some assays, the wild-type behavioral responses
were signiﬁcantly different between the B6 and B6D2F1
lines of mice, which was expected given the long history of
differences between various inbred strains and F1 hybrid
lines (Balogh and Wehner 2003; Logue et al. 1997;
Upchurch et al. 1988). These expected differences between
wild-type lines might make the interpretation of the effect
of the R6/2 transgene on particular phenotypes more
challenging. However, the relevant comparisons for the
effect of the R6/2 transgene on behavior are with the
appropriate control. Abnormal responses due to the pres-
ence of the transgene are most suitably evaluated relative
to wild-type littermates of the same genetic background.
Therefore, we do not believe that differences in wild-type
responses between the two lines have signiﬁcantly con-
founded the interpretations of the dominant modiﬁer
effects observed in the D2B6F1 110Q mice.
In several of the phenotypes tested, the presence of the
D2 allele appeared to attenuate the expected R6/2 pheno-
type based on the response observed in the congenic B6
line. For example, signiﬁcant delay of morbidity was
observed in B6D2F1 transgenic mice. In addition, explor-
atory activity and body weight were strongly inﬂuenced by
the presence of the D2 allele.
Activity was dramatically reduced in transgenics of the
B6 line, replicating our previous observations (Cowin et al.
2011). In contrast, we found no difference in the amount of
exploration between wild-type and transgenic mice in the
B6D2F1 hybrid line. In addition, transgenic F1 mice were
found to exhibit increased activity relative to B6 trans-
genics. Taken together, these results suggest attenuation of
the reduced-activity phenotype. However, because
B6D2F1 wild-type mice exhibited reduced exploration
relative to B6 controls, one could argue that the reason the
activity of the R6/2 mice on the B6D2F1 background was
not signiﬁcantly impaired relative to their wild-type lit-
termates was because the wild-type exploration was
already reduced. While this is certainly possible, we
believe close examination of the data do not support this
argument. Although the B6D2F1 wild-type behavior was
lower than that of the B6 mice, there is still ample
opportunity for the B6D2F1 transgenic mice to show fur-
ther reduced activity. That is, there is little concern for a
ﬂoor effect, as clearly evidenced by the even further
decreased exploration of B6 R6/2 mice. Thus, we believe
the interpretation that reduced activity is attenuated with
the D2 allele is appropriate. If F1 R6/2 mice were impaired
in open-ﬁeld exploration, the expected result would be that
the F1 transgenic mice would show signiﬁcantly reduced
total distance measures relative to the F1 wild-type mice
and likely exhibit reduced exploration relative to B6
transgenic mice. Instead, transgenic F1 male performance
was indistinguishable from exploration activity in wild-
type males on the same genetic background, while female
F1 transgenics showed greater exploration than wild-type
female mice.
Fig. 7 TR-FRET analysis of soluble and aggregated mHTT protein.
B6D2F1 mice show increased soluble mHTT but no difference in
aggregated protein levels. ‘‘b’’ denotes the increased soluble mHTT
between B6 and B6D2F1 transgenic mice. All P = 0.016 by one-way
ANOVA
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110Q mice on the B6 genetic background was ameliorated
in R6/2 110Q mice on the B6D2F1 hybrid background.
Weight loss is a well-documented characteristic of late-
stage disease pathology in HD patients. In the present
study, wild-type mice from both B6 and B6D2F1 back-
grounds maintained similar weights and reduced-weight
phenotypes were observed only in transgenic mice in the
B6 background. It is important to note, however, that the
delayed morbidity observed in transgenic B6D2F1 mice
may result in a delay in the weight-loss phenotype and that
this phenotype would be observed at later ages. Although
weight loss is among one of the earliest phenotypes to
occur in the B6 R6/2 mice (Cowin et al. 2011) and B6D2F1
transgenic mice showed several overt phenotypes by
8 weeks of age, the possibility that the presence of the D2
allele may alter the timeline of this phenotype cannot be
excluded in the present study.
However, not all phenotypes tested showed apparent
improvement by the presence of a single D2 allele. Exac-
erbation of impairment was observed in the rotarod motor
performance on this assay. Although modiﬁcation of phe-
notypes in either direction (i.e., amelioration or enhance-
ment) is expected in any dominant modiﬁer screen, the
results of the rotarod assay in this study were surprisingly
incongruent with the improvement in transgenic F1 activity
measures of the open ﬁeld. These data clearly show that the
motor and activity phenotypes are separable and may be
modiﬁed by different genes or the same proteins acting in
different pathways or cell types.
Still other HD-related symptoms previously observed in
congenic B6 R6/2 mice were not altered in transgenic
mice. Speciﬁcally, anxiety-related behavior, as indicated
by the center:total distance ratio in the open-ﬁeld assay,
was found to be generally increased in both transgenic and
wild-type B6D2F1 mice relative to B6 animals, but trans-
genic mice in both backgrounds were found to exhibit more
anxiety-like behavior than wild-type littermates. While it is
clear that dominant genetic modiﬁers exist in the D2
genetic background to increase anxiety-like behaviors in
wild-type mice (as measured in the open ﬁeld), the effects
that the unknown modiﬁer genes exert on behavior do not
alter HD-like symptoms in the R/62 mice and therefore do
not appear to interact with the disease mechanism causing
the anxiety-like phenotype.
In other assays, the pattern of data was complicated
making interpretation more difﬁcult. For example, PPI
revealed an overall effect of genetic background in
‘‘baseline’’ or ‘‘normal’’ performance of both wild-type and
transgenic animals in the B6D2F1 background. Startle
amplitudes were signiﬁcantly lower in F1 mice of both
genotypes relative to B6 mice. Interestingly, despite
decreased startle amplitudes, PPI data showed the F1
background to have improved inhibition relative to B6
mice. Again, this pattern of data suggests that any changes
due to genetic background modiﬁcation that are observed
between the B6 and F1 lines are limited to dominant effects
on baseline behaviors in the presence of a D2 allele and are
likely not directly impacting the disease mechanism for this
trait. It is important to note that although no dominant
modiﬁcation of the R6/2 transgenic phenotype was iden-
tiﬁed in the B6D2F1 background for anxiety or sensori-
motor gating, these ﬁndings do not refute the existence of
recessive modiﬁers or negate the possibility of ﬁnding
modiﬁcation in another background strain.
Behavioral phenotypes were not the only measures of
disease exhibited by R6/2 mice that showed modulation
by the presence of a D2 allele. Soluble protein levels of
mHTT were also observed to be altered by genetic
background which suggests the presence of dominant
modiﬁers. Interestingly, no modiﬁcation of aggregated
protein levels was observed. Taken together with the
delayed morbidity and amelioration of other phenotypes
in B6D2F1 mice, the increased levels of soluble protein
without similarly increased aggregated protein levels may
suggest improved clearance of the mutant protein or
simply delayed aggregation of the increased levels of
soluble protein.
The present study presents the ﬁrst data from an ongoing
modiﬁer screen for dominant genetic modiﬁers of HD-like
phenotypes in R6/2 mice. The presentation of a single D2
allele in the B6 background showed dominant effects on
the R6/2 phenotype, both ameliorating and exacerbating
the R6/2 disease phenotypes. While further insights into
phenotypes showing amelioration may be gained through
additional studies of B6D2F1 mice at later ages, we con-
sider the characterization of the precise age of onset in F1
mice to be of lower priority and less interesting than the
search for modiﬁer genes.
Unlike traditional mammalian modiﬁer screens that use
ENU mutagenesis to mutate random genes in hopes of
identifying novel proteins to further elucidate a known
pathway (Beier and Herron 2004; Justice et al. 1999), this
study presents dominant modiﬁcation by the addition of
normal, unmutated genes expressed in a different genetic
background. An unbiased modiﬁer screen based on
genetic variation rather than random mutation is likely to
prove extremely valuable in the study of human diseases
in which traits or symptoms are strongly hereditary and
correlate with family history (i.e., genetic background).
Using B6XD2 recombinant inbred strains and mapping
QTLs (quantitative trait loci), we hope to identify genes
that confer differential and dominant modulation of HD-
like phenotypic expression in the R6/2 mouse. Identifying
genes that modify the HD symptoms may lead to novel
targets for treatment as well as to help elucidate the
R.-M. Cowin et al.: Genetic background modulates behavioral impairments in R6/2 mice 375
123molecular mechanisms of HD pathogenesis that may
eventually lead to a cure.
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